ES2974542T3 - Formulaciones orales de inhibidores del sarcómero cardíaco - Google Patents
Formulaciones orales de inhibidores del sarcómero cardíaco Download PDFInfo
- Publication number
- ES2974542T3 ES2974542T3 ES20753563T ES20753563T ES2974542T3 ES 2974542 T3 ES2974542 T3 ES 2974542T3 ES 20753563 T ES20753563 T ES 20753563T ES 20753563 T ES20753563 T ES 20753563T ES 2974542 T3 ES2974542 T3 ES 2974542T3
- Authority
- ES
- Spain
- Prior art keywords
- approximately
- weight
- core
- total weight
- intragranular
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4245—Oxadiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
- A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2095—Tabletting processes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Cardiology (AREA)
- Hospice & Palliative Care (AREA)
- Heart & Thoracic Surgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962875358P | 2019-07-17 | 2019-07-17 | |
| PCT/US2020/042389 WO2021011808A1 (en) | 2019-07-17 | 2020-07-16 | Cardiac sarcomere inhibitor oral formulations |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2974542T3 true ES2974542T3 (es) | 2024-06-27 |
Family
ID=71995104
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES20753563T Active ES2974542T3 (es) | 2019-07-17 | 2020-07-16 | Formulaciones orales de inhibidores del sarcómero cardíaco |
Country Status (25)
| Country | Link |
|---|---|
| US (1) | US20220265612A1 (https=) |
| EP (1) | EP3999038B1 (https=) |
| JP (1) | JP7623342B2 (https=) |
| KR (1) | KR20220082804A (https=) |
| CN (1) | CN114765954B (https=) |
| AU (1) | AU2020315642B2 (https=) |
| BR (1) | BR112022000495A2 (https=) |
| CA (1) | CA3144972A1 (https=) |
| CL (1) | CL2022000108A1 (https=) |
| DK (1) | DK3999038T3 (https=) |
| ES (1) | ES2974542T3 (https=) |
| FI (1) | FI3999038T3 (https=) |
| HR (1) | HRP20240200T1 (https=) |
| HU (1) | HUE065712T2 (https=) |
| IL (1) | IL289884B2 (https=) |
| LT (1) | LT3999038T (https=) |
| MX (1) | MX2022000708A (https=) |
| PH (1) | PH12022550083A1 (https=) |
| PL (1) | PL3999038T3 (https=) |
| PT (1) | PT3999038T (https=) |
| RS (1) | RS65302B1 (https=) |
| SI (1) | SI3999038T1 (https=) |
| SM (1) | SMT202400107T1 (https=) |
| TW (1) | TW202519217A (https=) |
| WO (1) | WO2021011808A1 (https=) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019144041A1 (en) | 2018-01-19 | 2019-07-25 | Cytokinetics, Inc. | Dihydrobenzofuran and inden analogs as cardiac sarcomere inhibitors |
| JP7610985B2 (ja) | 2018-06-26 | 2025-01-09 | サイトキネティックス， インコーポレイテッド | 心臓サルコメア阻害剤 |
| JP7438148B2 (ja) | 2018-06-26 | 2024-02-26 | サイトキネティックス， インコーポレイテッド | 心臓サルコメア阻害剤 |
| MA53491A (fr) | 2018-08-31 | 2021-09-15 | Cytokinetics Inc | Inhibiteurs de sarcomes cardiaques |
| CN117083275A (zh) | 2021-03-04 | 2023-11-17 | 赛特凯恩蒂克公司 | 心脏肌节抑制剂 |
| PT4370116T (pt) | 2021-07-16 | 2025-03-14 | Cytokinetics Inc | Regimes de administração de aficamten para o tratamento da cardiomiopatia hipertrófica obstrutiva |
| WO2024020468A1 (en) | 2022-07-20 | 2024-01-25 | Cytokinetics, Incorporated | Methods for treating non-obstructive hypertrophic cardiomyopathy |
| EP4565230A1 (en) | 2022-08-04 | 2025-06-11 | Cytokinetics, Inc. | Methods for treating obstructive hypertrophic cardiomyopathy |
| WO2024179422A1 (zh) * | 2023-03-02 | 2024-09-06 | 苏州科睿思制药有限公司 | Aficamten的共晶及其制备方法和用途 |
| US20250295639A1 (en) | 2024-03-20 | 2025-09-25 | Cytokinetics, Incorporated | Methods for treating heart diseases |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2007027855A2 (en) * | 2005-09-01 | 2007-03-08 | Array Biopharma Inc. | Raf inhibitor compounds and methods of use thereof |
| NZ598744A (en) * | 2009-09-18 | 2013-11-29 | Sanofi Sa | (z)-2-cyano-3-hydroxy-but-2-enoic acid-(4'-trifluormethylphenyl)-amide tablet formulations with improved stability |
| US20130273096A1 (en) * | 2011-10-05 | 2013-10-17 | Bruce A. Daniels | Therapeutic Sulfated Polysaccharides, Compositions Thereof, and Methods for Treating Patients |
| WO2013112804A1 (en) * | 2012-01-25 | 2013-08-01 | Vertex Pharmaceuticals Incorporated | Formulations of 3-(6-(1-(2.2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid |
| US9199945B2 (en) * | 2013-06-21 | 2015-12-01 | MyoKardia, Inc. | Cycloalkyl-substituted pyrimidinedione compounds |
| US20170087180A1 (en) * | 2014-06-03 | 2017-03-30 | Sulfagenix, Inc. | Methods and compositions for treating nitric oxide deficiency disorders and related conditions |
| US9902702B2 (en) * | 2014-07-15 | 2018-02-27 | Bristol-Myers Squibb Company | Spirocycloheptanes as inhibitors of rock |
| ES2969565T3 (es) * | 2015-09-30 | 2024-12-13 | Max Planck Ges Zur Foerderung Derwissenschaften E V | Derivados heteroarílicos como inhibidores de la sepiapterina reductasa |
| WO2019144041A1 (en) * | 2018-01-19 | 2019-07-25 | Cytokinetics, Inc. | Dihydrobenzofuran and inden analogs as cardiac sarcomere inhibitors |
-
2020
- 2020-07-16 RS RS20240236A patent/RS65302B1/sr unknown
- 2020-07-16 LT LTEPPCT/US2020/042389T patent/LT3999038T/lt unknown
- 2020-07-16 HR HRP20240200TT patent/HRP20240200T1/hr unknown
- 2020-07-16 EP EP20753563.4A patent/EP3999038B1/en active Active
- 2020-07-16 DK DK20753563.4T patent/DK3999038T3/da active
- 2020-07-16 PT PT207535634T patent/PT3999038T/pt unknown
- 2020-07-16 WO PCT/US2020/042389 patent/WO2021011808A1/en not_active Ceased
- 2020-07-16 KR KR1020227003543A patent/KR20220082804A/ko active Pending
- 2020-07-16 FI FIEP20753563.4T patent/FI3999038T3/fi active
- 2020-07-16 CN CN202080062806.7A patent/CN114765954B/zh active Active
- 2020-07-16 ES ES20753563T patent/ES2974542T3/es active Active
- 2020-07-16 BR BR112022000495A patent/BR112022000495A2/pt unknown
- 2020-07-16 HU HUE20753563A patent/HUE065712T2/hu unknown
- 2020-07-16 PH PH1/2022/550083A patent/PH12022550083A1/en unknown
- 2020-07-16 TW TW113138679A patent/TW202519217A/zh unknown
- 2020-07-16 US US17/627,600 patent/US20220265612A1/en active Pending
- 2020-07-16 MX MX2022000708A patent/MX2022000708A/es unknown
- 2020-07-16 AU AU2020315642A patent/AU2020315642B2/en active Active
- 2020-07-16 SM SM20240107T patent/SMT202400107T1/it unknown
- 2020-07-16 SI SI202030397T patent/SI3999038T1/sl unknown
- 2020-07-16 CA CA3144972A patent/CA3144972A1/en active Pending
- 2020-07-16 JP JP2022502218A patent/JP7623342B2/ja active Active
- 2020-07-16 PL PL20753563.4T patent/PL3999038T3/pl unknown
- 2020-07-16 IL IL289884A patent/IL289884B2/en unknown
-
2022
- 2022-01-15 CL CL2022000108A patent/CL2022000108A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| PH12022550083A1 (en) | 2023-04-12 |
| PL3999038T3 (pl) | 2024-05-13 |
| TW202116307A (zh) | 2021-05-01 |
| RS65302B1 (sr) | 2024-04-30 |
| IL289884B1 (en) | 2025-09-01 |
| IL289884A (en) | 2022-03-01 |
| MX2022000708A (es) | 2022-02-23 |
| BR112022000495A2 (pt) | 2022-03-03 |
| IL289884B2 (en) | 2026-01-01 |
| NZ784934A (en) | 2025-03-28 |
| US20220265612A1 (en) | 2022-08-25 |
| AU2020315642B2 (en) | 2026-04-02 |
| CL2022000108A1 (es) | 2022-10-21 |
| DK3999038T3 (da) | 2024-03-18 |
| KR20220082804A (ko) | 2022-06-17 |
| HRP20240200T1 (hr) | 2024-04-26 |
| FI3999038T3 (fi) | 2024-02-21 |
| EP3999038A1 (en) | 2022-05-25 |
| TW202519217A (zh) | 2025-05-16 |
| PT3999038T (pt) | 2024-03-14 |
| AU2020315642A1 (en) | 2022-03-03 |
| CN114765954B (zh) | 2024-01-02 |
| JP7623342B2 (ja) | 2025-01-28 |
| JP2022542804A (ja) | 2022-10-07 |
| EP3999038B1 (en) | 2024-01-10 |
| LT3999038T (lt) | 2024-03-25 |
| SMT202400107T1 (it) | 2024-05-14 |
| WO2021011808A1 (en) | 2021-01-21 |
| HUE065712T2 (hu) | 2024-06-28 |
| CA3144972A1 (en) | 2021-01-21 |
| SI3999038T1 (sl) | 2024-05-31 |
| CN114765954A (zh) | 2022-07-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2974542T3 (es) | Formulaciones orales de inhibidores del sarcómero cardíaco | |
| TWI865562B (zh) | (r)-n-(5-(5-乙基-1,2,4-二唑-3-基)-2,3-二氫-1h-茚-1-基)-1-甲基-1h-吡唑-4-羧醯胺之多晶型物 | |
| ES2390661T5 (es) | Forma de presentación para administración por vía oral para éster etílico de ácido 3-[(2-{[4-(hexiloxicarbonilamino-imino-metil)-fenilamino]-metil}-1-metil-1H-bencimidazol-5-carbonil)-piridin-2-il-amino]-propiónico o sus sales | |
| JP2020172531A (ja) | 統合失調症を治療するための２−（（１−（２（４−フルオロフェニル）−２−オキソエチル）ピペリジン−４−イル）メチル）イソインドリン−１−オン | |
| BR112019017644A2 (pt) | Forma cristalina de {5-(4-bromo-fenil)-6-[2-(5-bromo-pirimidina-2-iloxi)-etoxi]-pirimidina-4-il}-sulfamida, composição farmacêutica, uso de uma forma cristalina do composto {5-(4-bromo-fenil)-6-[2-(5-bromo-pirimidina-2-iloxi)-etoxi]-pirimidina-4-il}-sulfamida, e, método de tratamento | |
| ES2982707T3 (es) | Polimorfos de (R)-N-(5-(5-isopropil-1,2,4-oxadiazol-3-il)-2,3-dihidro-1H-inden-1-il)-2-metil-2H-tetrazol-5-carboxamida | |
| US20100087481A1 (en) | Oral pharmaceutical formulations for antidiabetic compounds | |
| CN102485724A (zh) | 取代噻唑基吡唑并吡啶类化合物及其医药用途 | |
| CN119998292A (zh) | 5-(3,4-二氟苄基)-8-((1r,4r)-4-甲基环己基)-6,9-二氧代基-2,5,8-三氮杂螺[3.5]壬烷-2-甲醛的结晶形式 | |
| CA3137138A1 (en) | Methods of treating hypertension with activators of tie-2 | |
| RU2823999C2 (ru) | Пероральные композиции ингибиторов сердечного саркомера | |
| JP5925862B2 (ja) | セロトニン受容体介在状態を治療する方法及び組成物 | |
| TWI917329B (zh) | 心臟肌小節抑制劑口服調配物 | |
| HK40077275A (en) | Cardiac sarcomere inhibitor oral formulations | |
| HK40077275B (zh) | 心脏肌节抑制剂口服制剂 | |
| ES2463190A2 (es) | Formas cristalinas de sartanes tales como telmisartán con betabloqueantes | |
| ES2653801T3 (es) | Sustancia seleccionada entre midodrina, una sal farmacéutica y el metabolito activo de la misma, para uso en el tratamiento de cardiopatía obstructiva | |
| RU2846046C2 (ru) | Полиморфы (r)-n-(5-(5-этил-1,2,4,-оксадиазол-3-ил)-2,3-дигидро-1н-инден-1-ил)-1-метил-1н-пиразол-4-карбоксамида | |
| HK40076616A (en) | Polymorphs of (r)-n-(5-(5-ethyl-1,2,4-oxadiazol-3-yl)-2,3-dihydro-1h-inden-1-yl)-1-methyl-1h-pyrazole-4-carboxamide |